Phase 4 N=30 Continuous Double Ovarian Stimulation.
Fertility Issues
Primary: Total Number of Retrieved Oocytes — 13.33; 11.87 oocytes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=112 Follicular Steroid Genesis in Controlled Ovarian Stimulation
Infertility · Controlled Ovarian Hyperstimulation
Primary: SERUM PROGSTERONE CONCENTRATION — 0.74; 0.45 ng/mL — p=<0.05
Phase 4 N=710 FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST)
Infertility
Primary: Clinical Pregnancy Rate — 36.93; 39.66 percentage of participants — p=0.49
Phase 4 N=442 Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)
Infertility
Primary: Total Number of Oocytes — 12.4; 12.1 Number of oocytes
Phase 3 N=176 A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation
Infertility
Primary: Number of Oocytes Retrieved — 7.1; 7.3; 6.6 Number of oocytes
Phase 3 N=105 Administration of Follicle-stimulating Hormone (FSH) and Low Dose Human Chorionic Gonadotropin (hCG) for Oocyte Maturity While Decreasing hCG Exposure in In Vitro Fertilization (IVF) Cycles
Infertility
Primary: Total Fertilization Proportion (i.e. Total Competent Proportion) — 0.59; 0.65 ratio
Phase 4 N=110 Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)
Polycystic Ovarian Syndrome · Infertility
Primary: Participants With Cycle Cancellation Due to Risk of Ovarian Hyperstimulation Syndrome (OHSS) Between Weeks 1 - 3 — 1; 0; 1; 0 Participants — p=1.000
Phase 3 N=27 Immunogenicity of Repeated Follicle Stimulating Hormone (FSH) Stimulation Cycles
Oocyte Donation
Primary: Number of Patients Producing Anti-FSH Antibodies. — 0 participants
N/A N=20 The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors
Ovarian Hyperstimulation Syndrome
Primary: Volume of Ascites in the Abdomen is Indicative of the Severity of OHSS — 10 cc (volume of ascites)
Phase 4 N=188 Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial
Infertility
Primary: Mean Fertilization Proportion (2PN/Oocytes Collected) — 0.63; 0.55 proportion of oocytes fertilized
Early Phase 1 N=100 Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS
Polycystic Ovary Syndrome · Infertility
Primary: Ovulation Rate — 93; 108 percentage of all cycles
Phase 4 N=310 Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction
Ovulation Induction
Primary: Percentage of Participants With a Mono-follicular Development — 56.55; 55.20 percentage of participants — p=0.9560
N/A N=190 Cumulative Pregnancy Rate With Lower and Higher Gonadotropin Dose During IVF Among Poor Responders
Infertility · Ovarian Dysfunction
Primary: Cumulative Clinical Pregnancy Rate — 27; 17 Participants
Phase 3 N=1,390 Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)
Infertility
Primary: Percentage of Participants With a Vital Pregnancy — 23.9; 26.9 percentage of participants
Phase 3 N=136 Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)
Polycystic Ovarian Syndrome
Primary: Estradiol (E2) Levels on r-hCG Day — 1668.86; 1672.80 picogram/milliliter (pg/mL)
Phase 3 N=900 Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation
Pregnancy · Unexplained Infertility
Primary: Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH. — 9; 8; 34 number of multiples
Phase 4 N=200 CONSORT Randomized Controlled Trial in Assisted Reproductive Technology
Infertility
Primary: Number of Oocytes Retrieved Per Participant — 10.0; 11.8 oocytes — p=0.037
Phase 3 N=1,509 A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)
In Vitro Fertilization
Primary: Percentage of Participants With an Ongoing Pregnancy (Ongoing Pregnancy Rate) — 39.0; 38.1 Percentage of participants
N/A N=30 Aspiration of Limited Number of Follicles to Prevent Severe Ovarian Hyperstimulation Syndrome
Infertility
Primary: Number of Participants of Severe Ovarian Hyperstimulation Syndrome — 2; 11 participants
Phase 4 N=23 Maximal Stimulation and Delayed Fertilization for Diminished Ovarian Reserve: a Randomized Pilot Study
Infertility
Primary: Oocytes — 19; 47 oocytes
Phase 3 N=1,011 Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian Women
Controlled Ovarian Simulation
Primary: Ongoing Pregnancy Rate — 31.3; 25.7 percentage of participants
Phase 3 N=60 Comparative Study Between Minidose Long Protocol and Microdose Flare Protocol in Controlled Ovarian Hyperstimulation
Infertility
Primary: Number of Oocytes Retrieved — 4; 3.4 oocytes
Phase 3 N=397 To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)
Infertility
Primary: Number of Cumulus-oocyte-complexes Retrieved, Per Attempt — 13.3; 10.6 Number of cumulus-oocyte-complexes — p=<0.001
Phase 4 N=100 Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART)
Controlled Ovarian Stimulation · Infertility
Primary: The Oestradiol Concentration on the Day of Ovulation Induction — 11482; 12262 pmol/L
Phase 2 N=131 A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve
Infertility · Ovulation Induction
Primary: Mean Number of Metaphase II (M-II) Oocytes Retrieved — 6.7; 7.0 M-II oocytes
Phase 4 N=71 Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS
Ovarian Hyperstimulation Syndrome
Primary: Ongoing Pregnancy — 15; 19 participants
Phase 4 N=3 Ovulation Trigger With hCG Compared to GnRH Agonist in Patients With Repeated IVF Failures
Infertility
Primary: Fetal Heart Activity 1 Month After Oocyte Retrieval — 0; 0 participants with fetal heart activity
Phase 3 N=233 A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703)
Controlled Ovarian Stimulation
Primary: The Amount of International Units (IU) of Recombinant Follicle Stimulating Hormone (recFSH) Needed in a Controlled Ovarian Stimulation (COS) Cycle up to the First Day…
Phase 2 N=60 Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis
Endometriosis · Ovarian Hyperstimulation
Primary: Average Delta in Endometriosis Pain Score Pre and Post Stimulation With and Without Use Of Letrozole — -2.5; -2.7 Change in score on a scale
Phase 3 N=82 Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome
Polycystic Ovary Syndrome
Primary: Percentage of Participants With Ovulation Detected by Ultrasound — 52.5; 40.4 percentage of participants — p=0.3